310 related articles for article (PubMed ID: 24993868)
1. Five-year nationwide follow-up study of active surveillance for prostate cancer.
Loeb S; Folkvaljon Y; Makarov DV; Bratt O; Bill-Axelson A; Stattin P
Eur Urol; 2015 Feb; 67(2):233-8. PubMed ID: 24993868
[TBL] [Abstract][Full Text] [Related]
2. Outcome following active surveillance of men with screen-detected prostate cancer. Results from the Göteborg randomised population-based prostate cancer screening trial.
Godtman RA; Holmberg E; Khatami A; Stranne J; Hugosson J
Eur Urol; 2013 Jan; 63(1):101-7. PubMed ID: 22980443
[TBL] [Abstract][Full Text] [Related]
3. A Decade of Active Surveillance in the PRIAS Study: An Update and Evaluation of the Criteria Used to Recommend a Switch to Active Treatment.
Bokhorst LP; Valdagni R; Rannikko A; Kakehi Y; Pickles T; Bangma CH; Roobol MJ;
Eur Urol; 2016 Dec; 70(6):954-960. PubMed ID: 27329565
[TBL] [Abstract][Full Text] [Related]
4. Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers.
Bokhorst LP; Alberts AR; Rannikko A; Valdagni R; Pickles T; Kakehi Y; Bangma CH; Roobol MJ;
Eur Urol; 2015 Nov; 68(5):814-21. PubMed ID: 26138043
[TBL] [Abstract][Full Text] [Related]
5. Long-term Results of Active Surveillance in the Göteborg Randomized, Population-based Prostate Cancer Screening Trial.
Godtman RA; Holmberg E; Khatami A; Pihl CG; Stranne J; Hugosson J
Eur Urol; 2016 Nov; 70(5):760-766. PubMed ID: 27090975
[TBL] [Abstract][Full Text] [Related]
6. Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium.
Van Hemelrijck M; Ji X; Helleman J; Roobol MJ; van der Linden W; Nieboer D; Bangma CH; Frydenberg M; Rannikko A; Lee LS; Gnanapragasam VJ; Kattan MW; ;
Eur Urol; 2019 Mar; 75(3):523-531. PubMed ID: 30385049
[TBL] [Abstract][Full Text] [Related]
7. Population-based study of grade progression in patients who harboured Gleason 3 + 3.
Sampurno F; Earnest A; Millar J; Frydenberg M; Murphy D; Delprado W; Evans S
World J Urol; 2017 Nov; 35(11):1689-1699. PubMed ID: 28500489
[TBL] [Abstract][Full Text] [Related]
8. Refined Analysis of Prostate-specific Antigen Kinetics to Predict Prostate Cancer Active Surveillance Outcomes.
Cooperberg MR; Brooks JD; Faino AV; Newcomb LF; Kearns JT; Carroll PR; Dash A; Etzioni R; Fabrizio MD; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Lin DW; Zheng Y
Eur Urol; 2018 Aug; 74(2):211-217. PubMed ID: 29433975
[TBL] [Abstract][Full Text] [Related]
9. Uptake of Active Surveillance for Very-Low-Risk Prostate Cancer in Sweden.
Loeb S; Folkvaljon Y; Curnyn C; Robinson D; Bratt O; Stattin P
JAMA Oncol; 2017 Oct; 3(10):1393-1398. PubMed ID: 27768168
[TBL] [Abstract][Full Text] [Related]
10. A "PSA pyramid" for men with initial prostate-specific antigen ≤3 ng/ml: a plea for individualized prostate cancer screening.
Randazzo M; Beatrice J; Huber A; Grobholz R; Manka L; Chun FK; Recker F; Kwiatkowski M
Eur Urol; 2015 Oct; 68(4):591-7. PubMed ID: 24794075
[TBL] [Abstract][Full Text] [Related]
11. Improving the Specificity of Screening for Lethal Prostate Cancer Using Prostate-specific Antigen and a Panel of Kallikrein Markers: A Nested Case-Control Study.
Stattin P; Vickers AJ; Sjoberg DD; Johansson R; Granfors T; Johansson M; Pettersson K; Scardino PT; Hallmans G; Lilja H
Eur Urol; 2015 Aug; 68(2):207-13. PubMed ID: 25682340
[TBL] [Abstract][Full Text] [Related]
12. Incidence of prostate cancer after termination of screening in a population-based randomised screening trial.
Grenabo Bergdahl A; Holmberg E; Moss S; Hugosson J
Eur Urol; 2013 Nov; 64(5):703-9. PubMed ID: 23721957
[TBL] [Abstract][Full Text] [Related]
13. Adverse Disease Features in Gleason Score 3 + 4 "Favorable Intermediate-Risk" Prostate Cancer: Implications for Active Surveillance.
Morlacco A; Cheville JC; Rangel LJ; Gearman DJ; Karnes RJ
Eur Urol; 2017 Sep; 72(3):442-447. PubMed ID: 27574819
[TBL] [Abstract][Full Text] [Related]
14. Obesity is associated with risk of progression for low-risk prostate cancers managed expectantly.
Bhindi B; Kulkarni GS; Finelli A; Alibhai SM; Hamilton RJ; Toi A; van der Kwast TH; Evans A; Hersey K; Jewett MA; Zlotta AR; Trachtenberg J; Fleshner NE
Eur Urol; 2014 Nov; 66(5):841-8. PubMed ID: 24954793
[TBL] [Abstract][Full Text] [Related]
15. Changing Trends in Surgical Management of Prostate Cancer: The End of Overtreatment?
Huland H; Graefen M
Eur Urol; 2015 Aug; 68(2):175-8. PubMed ID: 25736732
[TBL] [Abstract][Full Text] [Related]
16. Long-term outcomes among noncuratively treated men according to prostate cancer risk category in a nationwide, population-based study.
Rider JR; Sandin F; Andrén O; Wiklund P; Hugosson J; Stattin P
Eur Urol; 2013 Jan; 63(1):88-96. PubMed ID: 22902040
[TBL] [Abstract][Full Text] [Related]
17. Nine-year Follow-up for a Study of Diffusion-weighted Magnetic Resonance Imaging in a Prospective Prostate Cancer Active Surveillance Cohort.
Henderson DR; de Souza NM; Thomas K; Riches SF; Morgan VA; Sohaib SA; Dearnaley DP; Parker CC; van As NJ
Eur Urol; 2016 Jun; 69(6):1028-33. PubMed ID: 26482887
[TBL] [Abstract][Full Text] [Related]
18. Poor Follow-up After Elevated Prostate-specific Antigen Tests: A Population-based Cohort Study.
Aly M; Clements M; Weibull CE; Nordström T; Näslund E; Adolfsson J; Grönberg H
Eur Urol Focus; 2019 Sep; 5(5):842-848. PubMed ID: 29433987
[TBL] [Abstract][Full Text] [Related]
19. Pathologic Outcomes in Favorable-risk Prostate Cancer: Comparative Analysis of Men Electing Active Surveillance and Immediate Surgery.
Tosoian JJ; Sundi D; Trock BJ; Landis P; Epstein JI; Schaeffer EM; Carter HB; Mamawala M
Eur Urol; 2016 Apr; 69(4):576-581. PubMed ID: 26456680
[TBL] [Abstract][Full Text] [Related]
20. Value of Serial Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging-guided Biopsies in Men with Low-risk Prostate Cancer on Active Surveillance After 1 Yr Follow-up.
Hamoen EHJ; Hoeks CMA; Somford DM; van Oort IM; Vergunst H; Oddens JR; Smits GA; Bokhorst LP; Witjes JA; Rovers MM; Hulsbergen-van de Kaa CA; Barentsz JO
Eur Urol Focus; 2019 May; 5(3):407-415. PubMed ID: 29331622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
